Search results “Triple negative breast cancer research”
Risk factors for developing triple-negative breast cancer
Breast cancer is the most common cancer in women. Among the 1.67 million women diagnosed each year, 15% are diagnosed with triple-negative breast cancer (TNBC). More common in women under the age of 50, TNBC has limited treatment options and is associated with particularly poor survival rates. Knowing the signs and symptoms of breast cancer is essential for early diagnosis and treatment. For more information on TNBC, visit https://www.roche.com/dam/jcr:83655b8... Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 5723 Roche
What is triple-negative breast cancer? | Dana-Farber Cancer Institute
Researchers are actively looking for new treatments for triple-negative breast cancer, says Eric Winer, MD, chief of the Division of Women's Cancers at Dana-Farber's Susan F. Smith Center for Women's Cancers. For more information about breast cancer and how it is diagnosed, visit http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Breast-Cancer.aspx?phase=Before_Treatment
Triple-Negative Breast Cancer Survivor Tanya Hall
After her diagnosis with triple-negative breast cancer, Tanya Hall has undergone a series of treatments. She credits cancer research for the advances that led to her successful treatment. That's why she has joined with the American Association for Cancer Research (AACR) to run in the AACR Rock 'n' Roll Philadelphia Half Marathon on Sept. 18, 2016. Learn how you can join Tanya to support lifesaving cancer research at www.RunnersForResearch.org.
Triple Negative Breast Cancer Treatment
Dr. Lisa Newman, director of the Breast Cancer Program at Henry Ford Health System, discusses Triple Negative Breast Cancer among African American women with host, Dr. Lonnie Joe on Primary Care.
Views: 3285 HenryFordTV
Eleni Andreopoulou, ASCO 2018 – Advances in molecular therapy in triple-negative breast cancer
Editorial board member, Eleni Andreopoulou, from Weill Cornell Medical College in New York, US, discusses molecular subtyping and advances in molecularly-targeted therapy in triple-negative breast cancer. What are the major challenges of treating triple-negative breast cancer? (0:11) How have advances in molecular subtyping impacted on the treatment of triple negative-breast cancer? (1:50) What unmet needs remain in molecularly targeted breast cancer therapy? (2:36) What innovations in clinical trial design are facilitating the development of therapies for high-risk, early-stage breast cancer? (3:41) Speaker disclosures: Eleni Andreopoulou has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Views: 117 Touch Medical Media
Triple Negative Breast Cancer Research
Help support Vanderbilt's cancer research funding by clicking the support button on GE Healthymagination's Web site: http://challenge.healthymagination.com/health/Towards-Personalized-Therapy-for-Triple- Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of triple negative breast cancer which is often aggressive and difficult to treat. Now these cancer investigators are advancing their initial findings to clinical use by refining the molecular profiles for each cancer subtype, which will aid in the development of diagnostic tests for personalized therapy for patients.
Views: 752 Vanderbilt Health
Triple Negative Breast Cancer Research
Triple Negative Breast Cancer Research
Views: 30 CBS 42
In Focus: Triple Negative Breast Cancer
As many of you know, I was diagnosed with Triple Negative breast cancer. It was not a happy surprise to learn that some patients with this type of cancer have cells that do not respond to treatment.
Views: 10121 JoanLunden
Proposed Clinical Trial Could Change Triple Negative Breast Cancer Treatment
Triple-negative breast cancer is a moniker give to a particularly aggressive group of breast cancers that often affect younger women. Because triple-negative breast cancers are not homogenous, and every single patient responds differently to various chemotherapies, it’s difficult to predict which chemotherapy will best treat each patient's cancer. But the researchers at the UK Markey Cancer Center are working to change that paradigm. Markey’s Breast Translational Group is currently developing a proposed clinical trial that could take the guesswork out of prescribing the second round of chemotherapy by treating a set of animal model “avatars” with the different therapies to gauge the response. To donate to help Markey get this clinical trial started, go to ukmarkey.org/donate and select “Tribute Gift.”
George Somlo, M.D. - What is triple negative breast cancer? | City of Hope
City of Hope medical oncologist George Somlo, M.D., talks about triple-negative breast cancer, including risk factors, the role of breast cancer stem cells and future research directions. LEARN MORE George Somlo, M.D. - http://www.cityofhope.org/directory/people/somlo-george City of Hope Breast Cancer Program - http://www.cityofhope.org/breast Research and Clinical Trials -- http://clinicaltrials.coh.org/ ###################### CONNECT WITH CITY OF HOPE http://www.facebook.com/cityofhope http://www.twitter.com/cityofhope http://www.causes.com/cityofhope and more at http://www.cityofhope.org/getsocial ABOUT CITY OF HOPE City of Hope is a leading medical research, treatment and education center dedicated to preventing, treating and curing cancer, diabetes, HIV/AIDS and other life-threatening diseases. Our mission is to quickly turn research ideas into cures that help save patients' lives all over the world. Learn more at http://www.cityofhope.org.
Views: 3412 City of Hope
Patricia Prijatel on her Diagnosis with Triple-Negative Breast Cancer
Patricia Prijatel, author of Surviving Triple-Negative Breast Cancer: Hope, Treatment, and Recovery, explains the experience of her diagnosis and how it drove her to research this disease. Patricia Prijatel, E.T. Meredith Distinguished Professor Emerita at Drake University, has helped educate, motivate, support, and challenge people for the better part of three decades. She is a nationally published magazine writer, an award-winning teacher, and a well-respected writing coach. Her "Positives About Negative" blog has reached more than 100,000 readers and is one of the few sites that deals specifically with triple negative breast cancer. For more information: http://www.oup.com/us/catalog/general/subject/Medicine/Oncology/?view=usa&ci=9780195387629 (c) Oxford University Press USA.
Dr Fiona Simpson - Triple Negative Breast Cancer Research Discovery
Dr Fiona Simpson's research discovery fighting triple negative breast cancer, one of the more difficult breast cancer's to treat. This research is proudly funded by the PA Research Foundation. Find out more about Project Pink at www.projectpink.org.au. Donate to life-saving cancer research and help make pink just a pretty colour again.
Triple Negative Breast Cancer Researcher: Dr. Lisa A. Newman
Lisa A. Newman, MD, MPH, FACS, Director, Breast Care Center, Professor of Surgery at University of Michigan Comprehensive Cancer Center, discusses triple negative breast cancer research.
Views: 1950 TNBCFoundation
Triple Negative Breast Cancer Treatment Implications
Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Triple Negative Breast Cancer & Its First Targeted Therapy Research
Andres Forero, MD, Professor of Medicine, Division of Hematology/Oncology, and Experimental Therapeutics Program Co-Leader at University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, Alabama
Advances In Triple Negative Breast Cancer Treatment
Learn about the most recent research in treating triple-negative breast cancer treatment from medical oncologist David A. Margileth, MD. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Triple-negative Breast Cancer Clinical Trial Calling for Participants
An ongoing research program, led by Edith Mitchell, M.D., FACP, Clinical Professor of Medicine and Clinical Oncology at the Kimmel Cancer Center at Jefferson and Hallgeir Rui, M.D., Ph.D., Professor of Cancer Biology, has initiated a new clinical trial at the Kimmel Cancer Center at Thomas Jefferson University that offers a more customized and personalized approach to the treatment of triple-negative breast cancer. The trial, with lead investigators Drs. Tiffany Avery in the Department of Medical Oncology and Adam Berger in the Department of Surgery, offers treatment in the form of chemotherapy paired with a supplemental medication called a "Parp Inhibitor" and is designed to target the breast cancer cells to increase response to treatment and decrease the risk of recurrence. Researchers will conduct a randomized two-arm trial in 12-week cycles by administering different types of medicines in addition to chemotherapy. Triple-negative breast cancer cells lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces. This type of breast cancer diagnosis is more prevalent in younger women and in African-American women. Triple-negative breast cancers tend to grow faster and more aggressively and spread to other parts of the body more quicker than most other types of breast cancer. Drs. Mitchell and Rui and their team of researchers are hoping to increase the efficiency and effectiveness of treatment for triple-negative breast cancer through this clinical trial. If you think you may be a potential candidate for this clinical study, please contact the study coordinator, Melisa Mordenti, at 215-955-8979.
Views: 1167 PABreastCancer
DR. KIMBERLY KOSS - Koss National Triple Negative Breast Cancer Research Foundation
2016 Cincinnati Rotary Jefferson Award Finalist
Triple negative breast cancer | Dana-Farber Cancer Institute
Nancy Lin, MD, and Geoffrey Shapiro, MD, PhD, explain research and treatment in triple negative breast cancer to attendees at the fifth annual metastatic breast cancer forum for patients and families, held at Dana-Farber on September 24, 2016. Learn more about Dana=Farber’s program for patients with metastatic breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center/Metastatic-Breast-Cancer-Expertise.aspx
New treatment to triple negative breast cancer
New developments in breast cancer treatment. More info:
Views: 441 João Santos
New Triple Negative Breast Cancer Study Launched
Dr. Kristi Funk announces the launch of a new study for Triple Negative breast cancer patients, using Cynvenio's non-invasive liquid biopsy technology to identify and monitor early signs of metastasis.
Views: 22764 Pink Lotus Power Up
USciences 16th Annual Research Day: Anti-triple Negative Breast Cancer Compound
Jaspal Brar BI’18 presented research he has been doing in the lab of Bela Peethambaran PhD, focused on the use of Myrothamnus flabellifolius, a South African medicinal plant which contains extracts that are selectively toxic to breast cancer cells, while leaving healthy cells unaffected. Brar’s research showed that the compound made from the plant is effective to kill cancer cells but left the non-cancerous cells unharmed.
Views: 59 USciences
Blueberries: A Triple Threat Against Triple-Negative Breast Cancers
City of Hope cancer center researchers and study authors Shiuan Chen, Ph.D., and Lynn Adams, Ph.D. discuss the results of a research study on the effects of blueberries on breast cancer. Chen, research fellow Lynn S. Adams, Ph.D., and their colleagues applied blueberry extracts to TNBC cell cultures and found that blueberry extract not only inhibits proliferation and mobility in TNBC cells, it also led to cell death (apoptosis) at over twice the rate of untreated cells. Chen, Adams and others then tested blueberry extracts effectiveness in laboratory animal models. The researchers found that the blueberry groups TNBC tumor weight was 70 percent lighter than the control group and it also exhibited significantly lower proliferation and higher apoptosis activity. ################ CONNECT WITH US WEBSITE: http://www.cityofhope.org FACEBOOK: http://www.facebook.com/cityofhope TWITTER: http://www.twitter.com/cityofhope YOUTUBE: http://www.youtube.com/cityofhopeonline FLICKR: http://www.flickr.com/cityofhope BLOG: http://breakthroughs.cityofhope.org and MORE: http://www.cityofhope.org/getsocial ################ ABOUT CITY OF HOPE City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with clinics throughout southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit http://www.cityofhope.org.
Views: 7666 City of Hope
Beating Triple Negative Breast Cancer with Clinical Trial - Lehigh Valley Health Network
When Rochelle Eroh, of Hamburg, PA, was diagnosed with hormone receptor negative and HER2 neu negative (also known as triple negative) breast cancer, she quickly learned this was a more aggressive type of breast cancer. Given her young age and the size of her tumor, Lehigh Valley Health Network medical oncologist, Nicholas Lamparella, DO, provided Rochelle with information regarding a clinical trial for a neo-adjuvant chemotherapy regimen. She received the standard of care Paclitaxel, plus or minus two additional drugs, Carboplatin and Veliparib. In this video, Rochelle, breast cancer surgeon, Lori Alfonse, DO, and Rochelle's clinical trial nurse, Morgan Horton, describe Rochelle's experience and the additional level of care provided as part of the clinical trial. Lehigh Valley Health Network is part of the Memorial Sloan Kettering Cancer Alliance, an initiative to improve the quality of care and outcomes for patients with cancer in community health settings. Innovations at MSK, a world leader in cancer research, brings the latest treatments to community providers - and their patients - at an accelerated pace. For more information, call 610-402-CARE or go to LVHN.org/cancer.
Triple Negative Breast Cancer Foundation
The Triple Negative Breast Cancer Foundation's mission is to support research into the causes, diagnoses and treatment into triple negative breast cancer and provide programs and services to the triple negative breast cancer community. For more information, visit http://www.tnbcfoundation.org.
Views: 7214 TNBCFoundation
SMU Research: Women with Triple Negative breast cancer
Groundbreaking research looks at women fighting Triple Negative Breast Cancer — an aggressive subtype striking 10 to 20 percent of women with breast cancer — typically young, African-American/Hispanic, or testing positive for BRCA1 gene mutation, says psychologist Georita Frierson of Southern Methodist University.
Views: 722 SMUVideo
Dr. Susan Love Research Foundation: Triple Negative Breast Cancer Explained - Character Animation
Produced by: https://ripmediagroup.com was founded by a team of sales and marketing directors who developed creative, visual, and compelling campaigns that result in record setting growth. Rip Media Group focuses on increasing sales, creating demand, and generating growth in public as well as charitable organizations.
Views: 163 Rip Media Group
Triple-Negative Breast Cancer Patients Should Undergo Genetic Screening
Most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2, a Mayo Clinic-led study has found. The findings come from the largest analysis to date of genetic mutations in this aggressive form of breast cancer. The results of the research appear in the Journal of Clinical Oncology. Study author, Dr. Fergus Couch, comments
Views: 782 Mayo Clinic
Advancing Treatment for Patients with Advanced Triple Negative Breast Cancer
Source: https://www.spreaker.com/user/7078249/itunes-michael-pehl In this edition of The Onco’Zine Brief, recorded during the Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, June 1 - 5, 2018, Peter Hofland and Sonia Portillo talk with Michael Pehl, President and Chief Executive Officer of Immunomedics, a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC). At this year’s ASCO meeting, nearly 40,000 attendees gathered to discuss the growing body of data on advanced, difficult to treat diseases that do not have many treatment options. Hofland and Portillo speak with Pehl about some of the exciting developments that are taking place at this year’s meeting, including some of the data that his company presented about advancements in the development of targeted anti-cancer drugs such as antibody-drug conjugates. Traditional chemotherapy often fails to treat advanced or metastatic forms of cancer. This is because while chemotherapy disrupts tumors, it also harms other, healthy cells. In turn, this makes it difficult to deliver a potent anti-cancer drug, without causing too much harm to healthy cells. Antibody-drug conjugates on the other hand, are a form of targeted anti-cancer drugs that are able to target tumors cells, while sparing healthy cells. This means that more of an anti-cancer drugs can be delivered to the tumor, with less side effects. However, developing successful antibody-drug conjugates has remained a challenge for several decades. And to date only 4 different antibody-drug conjugates have been approved for the treatment of various forms of cancer. Hofland and Portillo ask Pehl how antibody-drug conjugate can be used for the treatment of advanced or metastatic triple negative breast cancer, a form of breast cancer that occurs in about 10% - 20% of all cases of breast cancer. In this type of cancer, the tumor cells lack the expression or amplification of targetable biomarkers, such as receptors for estrogen, progesterone, and human epidermal growth factor receptor 2, also known as HER2. Because in this type of cancer the cancer does not have the most common types of receptors known to fuel most cancer growth, common treatments like hormone therapy and drugs that target estrogen, progesterone, and HER2 are ineffective. Hence the name, triple negative. Using chemotherapy to treat triple negative breast cancer is still an effective option. In fact, triple negative breast cancer may respond even better to chemotherapy in the earlier stages than many other forms of cancer. But this type of cancer is extremely hard to treat, and – generally - has a poor prognosis. As many as 50% of patients diagnosed with early stage triple-negative breast cancer - that is stages 1 to 3 - experience disease recurrence, and 37% of patients die in the first 5 years after surgery. And while, as mentioned earlier, patients with metastatic or advanced triple-negative breast cancer may respond to chemotherapy, they do not always respond very well to traditional chemotherapy. These patients typically see a median progression free survival of only 3 to 4 months after failure of first-line of chemotherapy. Now, who are at risk for Triple negative breast cancer? As mention earlier, the disease occurs in about 10-20% of patients diagnosed breast cancers. The disease is also more likely to affect younger people, African Americans, Hispanics, and/or those with a BRCA1 gene mutation. In general, triple negative breast cancer can be more aggressive and difficult to treat. Also, the cancer is more likely to spread and recur. The stage of breast cancer and the grade of the tumor will influence the prognosis. For anti-cancer drug developers and oncologists treating this type of breast cancer, triple negative breast cancer is a major unmet medical need. To try meet this need, Immunomedics recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a new antibody-body drug conjugate for the treatment of patients with advanced or metastatic triple negative breast cancer who previously received at least two prior therapies for metastatic disease. Hofland and Portillo speak with Dr. Pehl about some of the latest data his company presented about a first-in-class drug – and how precision medicines for cancer, including antibody-drug conjugates, can be used for the treatment of advanced or metastatic triple negative breast cancer.
Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, Targets
In this presentation from the 14th Annual Best of San Antonio - Breast Cancer: Bench to Bedside, Dr. Debu Tripathy discusses novel therapeutics for the treatment of breast cancer, with a focus on HER2+ and triple negative disease. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
Views: 1090 ImedexCME
Triple-Negative Breast Cancer From Every Angle
Hear the latest about triple-negative breast cancer from our guest panelists, including some of the myths surrounding it and the research being done to find new treatments. The panel will also discuss side effects, the unique emotional concerns for people with TNBC and how to find a support system. About Our Panelists Helen L. Coons, PhD, ABPP is a board certified clinical health psychologist with over 25 years of professional experience with women and men with cancer, oncology health care providers and the cancer advocacy community. She routinely provides care to women across the life span with early and advanced breast, gynecologic and other cancer diagnoses before, during and after treatment, as well as women at “high risk” for cancer, and caregivers. Dr. Coons is a member of LBBC’s Medical Advisory Board and the advisory committee for an advanced breast cancer survey for Novartis' oncology division. Linda Cooper, LCSW, OSW-C is a licensed clinical social worker and a certified oncology social worker. She joined Rocky Mountain Cancer Centers in the spring of 2008. Linda has worked as a social worker in oncology and psychiatry services, hospitals and clinics, hospice programs, hospital emergency rooms, and geriatric settings. She is especially committed to working with older adults on their cancer journey and advocating for all cancer patients as they cope with quality of life issues. Moderator Janine E. Guglielmino, MA Senior Director, Programs and Partnerships Living Beyond Breast Cancer
Neelima Denduluri, MD -- Treatment of Triple Negative Breast Cancer
Neelima Denduluri, MD Treatment of Triple Negative Breast Cancer Oncology Outlook 2018 USA MCI
Treatment of Metastatic Triple-Negative Breast Cancer
Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC). Most trials reported today are in metastatic TNBC, but areas that need more attention are HER2+ disease and hormone-refractory hormone-receptor positive breast cancer, said Nanda. Knowledge of the role of immune checkpoint inhibition within these subtypes of breast cancer is needed as well. Nanda is also hoping combination therapy with immune checkpoint inhibitors, vaccines, and other therapies will help to improve the current response rates.
Views: 1147 Targeted Oncology
Dr. Carey on Treating Triple-Negative Breast Cancer
Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.
Views: 798 OncLiveTV
Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer
Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).
Views: 111 OncLiveTV
Milan Breast Cancer Conference 2009: Basal-like and triple negative breast cancer
Breast Cancer Pathology Research Group Lead Investigator Dr Ian O. Ellis talking at the 11th Milan Breast Cancer Conference. Nottingham System for grading breast cancer. Investigative tumour biology. Not every triple negative breast cancer is basal-like and vice-versa.
Views: 524 ecancer
Triple Negative Breast Cancer Awareness Day
There are many types of breast cancer. Triple negative breast cancer is one type that is in need of more research.
Saving Lives in Developing Countries: Downstaging triple negative breast cancer in Uganda
Dr. Constance Lehman speaks about a breast ultrasound project with the UCI/Hutchinson Center Cancer Alliance, a collaboration of the Uganda Cancer Institute in Kampala, Uganda, and Fred Hutchinson Cancer Research Center in Seattle. Lehman is a joint member of the Public Health Sciences Division at the Hutchinson Center, director of imaging at Seattle Cancer Care Alliance, and professor and vice chair of radiology and section head of breast imaging at the University of Washington Medical Center.
Views: 897 HutchinsonCenter1
Comment: Metastatic triple-negative breast cancer responds to immunotherapy
Dr Louis Weiner, (Lombardi Comprehensive Cancer Center, Washington D.C, USA) comments on Prof Leisha Emen's research for ecancertv at AACR 2015, He comments on how patients with triple-negative breast cancer have a worse prognosis than patients with other breast cancer subtypes, and in the United States, there is currently no targeted treatment available. He also discusses high hopes for future treatments with an investigational targeted immunotherapy under development directed at metastatic triple-negative breast cancer.
Views: 839 ecancer
AR+ Triple Negative Breast Cancer Clinical Trial
Learn about a phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer. http://www.bigtencrc.org
Triple-Negative Breast Cancer May Have New Treatment Option
Breastcancer.org Chief Medical Officer Marisa Weiss, M.D., brings you the latest news from the San Antonio Breast Cancer Symposium in our #SABCS15 video series! A study found that in women with triple-negative breast cancer, adding carboplatin to standard chemotherapy before surgery extended disease-free survival. Click here to learn more: http://www.breastcancer.org/research-news/triple-negative-may-have-new-tx-option.
Views: 369 Breastcancer.org
Triple-negative breast cancer: Adding carboplatin to presurgery chemotherapy improved survival
Prof Minckwitz talks to ecancertv at SABCS 2015 about his research into adding carboplatin to presurgery chemotherapy. According to results from the randomised phase II GeparSixto clinical trial there was improved disease-free survival for patients with triple-negative breast cancer.
Views: 710 ecancer
Genomically Directed Therapy for Triple Negative Breast Cancer
Do you have triple negative breast cancer? Did you have pre-operative chemotherapy with residual disease after surgery? You might be eligible for a clinical trial using an FDA-approved drug that is selected based on genetic differences in your tumor, versus the standard approach. Learn more: http://hoosiercancer.org/clinical-trials/trial/bre12-158/
Deciphering the Complexity: New Strategies for Triple-Negative Breast Cancer
Hear from our Komen Scholar, Dr. Jennifer Pietenpol, as she unwinds the complexity of triple negative breast cancer, and showcases how Komen funds have aided our understanding of triple negative breast cancer and helped pioneer novel treatment options and therapies. This webinar was hosted by: • Carrie Stovall, Director, Events • Michelle Martin-Pozo Ph.D., Director, Research Programs for Komen • Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, the B.F. Byrd Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology at Vanderbilt University School of Medicine Jennifer Pietenpol, Ph.D., began her research focused on the signaling of one of the most commonly mutated genes in all of cancer: p53. More recently, Dr. Pietenpol has combined her research expertise in molecular genetics with bioinformatics to identify differences of triple negative breast cancer. Her studies have helped lead to several clinical trials aimed to help oncologists determine the most appropriate and precise treatment for breast cancer patients. Dr. Pietenpol has been recognized many times for her leadership and her work, and continues to help lead and shape cancer research nationally as demonstrated by her recent appointment to a panel advising Vice President Joe Biden’s National Cancer Moonshot.
Views: 139 The 3-Day
Triple negative breast cancer Video Abstract 85442
Video abstract of an original research paper "Triple negative breast cancer: an Indian perspective", published in the open access journal Breast Cancer: Targets and Therapy by Akhtar et al. Introduction: Breast cancer is the most common female cancer in the world. Triple negative breast cancer (TNBC) is a recently identified biological variant with aggressive tumor behavior and poor prognosis. Data of hormonal status from the Indian population is scarce due to financial constraints in performing immunohistochemistry evaluation. The present study aims to prospectively analyze receptor status of all breast cancer patients and identify TNBC and compare their clinical profile and short term survival with other non-TNBC group. Materials and methods: All cytologically and histopathologically confirmed cases of carcinoma breast were prospectively enrolled. In a longitudinal study at tertiary care hospital in central India based on the hormonal status, they were further divided into TNBC and other groups. Comparison of risk factors, clinical profile and short-term survival was carried out. Results: A total 85 patients were enrolled and of them 37 (43.7%) were TNBC. On comparing risk factors ie, age, age at menarche, total reproductive age, age at first child birth, and menopausal status – no statistical significance was observed between the TNBC and non-TNBC groups. But on comparison of clinical profile TNBC tumors were significantly large with majority of patients presenting as locally advanced breast cancer (83%). No statistical difference was observed in axillary lymph node status between two groups. TNBC tumors were histologically more aggressive (grade 3) compared to other groups. No statistically significant difference was observed in short term overall survival but all three deaths were observed in the TNBC group only and two local recurrences after surgery were observed in the TNBC group. Conclusion: TNBC forms a large proportion of carcinoma breast patients in a central Indian scenario and needs more research to identify appropriate treatment planning considering aggressive histology and advanced presentation. Read the original research paper here: http://www.dovepress.com/triple-negative-breast-cancer-an-indian-perspective-peer-reviewed-article-BCTT
Views: 629 Dove Medical Press
Triple Negative Breast Cancer - Looking for a triple shot treatment
Triple Negative Breast Cancer - Looking for a triple shot treatment Group 14 - The John Doe's Aidan Bailey David Joubert Boyd Katoka Matthew Nocciolino Gunalini Packiakumar References 1. Chacon RD, Costanzo MV: Triple-negative breast cancer. Breast cancer research. 2010, 12 Suppl 2:S3. Link: http://www.biomedcentral.com/content/pdf/bcr2574.pdf 2. Feigin ME, Xue B, Hammell MC, Muthuswamy SK: G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. P Natl Acad Sci USA 2014, 111:4191-6. Link: http://www.pnas.org/content/111/11/4191.full.pdf
Stories of Hope: Terry Arnold, Triple-Negative Breast Cancer Patient
After a desperate, four-month search for a diagnosis, Terry Arnold received the news. Her doctor had discovered, not one, but two of the most deadly and aggressive forms of breast cancer. She had triple-negative breast cancer in both breasts and inflammatory breast cancer in her right breast. With his eyes full of tears, Arnold's doctor told her to get her affairs in order. She had a few months at best. Triple negative breast cancer (TNBC) differs from more common forms of breast cancer in that its cells lack estrogen and progesterone receptors. As a result, it spreads more quickly and doesn't respond to standard hormone therapy treatments. TNBC accounts for 10 to 20% of breast cancer cases in the U.S. and accounts for one of every four breast cancer-related deaths. While TNBC disproportionately strikes younger women, Arnold, a mother of five and grandmother of five, was 49 when she decided to get a second opinion at MD Anderson. "My doctor reran the tests and said, 'It's actually worse than your first doctor thought, but we think we can help you.' To have someone say that, was incredible," Arnold recalls. "I was very excited because he said, 'You'll be in treatment for 18 months, and it will be brutal.' I remember thinking that means he thinks I'm going to live 18 months. I was the happiest woman in the world because they had a plan. I just floated home." It's been six years since Arnold's diagnosis, and she's living cancer-free. She's used this time to form The IBC Network Foundation, which has donated more than $100,000 to breast cancer research at MD Anderson, and mentors hundreds of women fighting this disease. Arnold frequently picks up patients from the airport and meets them for their appointments, making sure they ask all the right questions. She also says she's been to more funerals than anyone should have to attend. "I've literally been with women from their first appointment to the day they rang that bell (to celebrate the end of treatment) and every step in between. To see them live when they were so ill, you just can't put a price tag on that," Arnold says. "I've also been with women minutes before they've died, and the privilege of being in a place that's so deep in their lives is something that very much drives me. Both the joys and the memories I share with these women provide encouragement and push me forward." A devout MD Anderson supporter, Arnold listened from the audience as the Moon Shots Program launched in 2012. She was overjoyed to hear that MD Anderson had selected her cancer, TNBC, as one of the six initial moon shots. "What this means to me is that women are going to live longer to raise their babies and have the impact on society they were meant to have. Without this research, none of that would be possible," Arnold says. "This disease is so brutal and progresses so quickly. We desperately need more research on TNBC. I'm alive and well after six years. That's not common. I think it can be, however, and I think MD Anderson is the place to make it happen." MD Anderson's Breast and Ovarian Cancers Moon Shot aims to combine the latest treatment technology and genetic knowledge to identify the most promising new treatments and move them to a clinical setting in a faster, more efficient way. It's a mission Arnold celebrates. "Private funding for research is more important than ever," she says. "And if MD Anderson is giving its time and resources to champion such a brutal disease, we need to support these efforts all the way." For more information and to make a donation, visit: cancermoonshots.org
Views: 4334 myGivingToMDAnderson
The Latest Research and Clinical Trials for ER+ and Triple-Negative Metastatic Breast Cancer
Nancy Lin, MD, medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana-Farber, discusses the latest treatment and research for ER+ and triple-negative breast cancers. This presentation was originally given at the Metastatic Breast Cancer Forum, held on Oct. 18, 2014 at Dana-Farber Cancer Institute.
Women raising awareness of triple negative breast cancer
Jennifer Griffin joins next generation of fundraisers Watch Gretchen Carlson and Jennifer Griffin talk about Breast Cancer and Cancer on The Real Story.
Views: 965 Fox News